Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- INTELLIGENT OPTICAL SYSTEMS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- NLDHG92SMX37
- Solicitation number
- PHS2007-2
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): Leishmaniasis is a disease endemic to India, Africa, Mediterranean nations, South American countries, and southern Texas. Americans visiting Latin American nations as tourists, and soldiers serving in Iraq and Afghanist
an, have contracted the disease. Polymerase chain reaction (PCR) and enzyme immunosorbent assays (ELISA) are commonly used to diagnose this disease. The current methods are laboratory based, require special equipment, involve complex procedures, and are la
bor intensive and time-consuming. ELISA tests for leishmaniasis are not highly specific and sensitive, so there is an important need to develop easy-to- use and highly sensitive diagnostic tests for leishmaniasis. In this project, Intelligent Optical Syste
ms, in collaboration with Professor Diane McMahon-Pratt of the Yale University School of Medicine, proposes to develop an easy-to-use and highly sensitive lateral flow immuno assay test strip for the accurate diagnosis of leishmaniasis. The conventional ap
proach for developing immunoassays for leishmaniasis involves the use of total Leishmania promastigotes as antigens. Using these antigens in the assay reduces the sensitivity, and also causes a cross reactivity problem with related diseases, such as Chagas
disease. This project involves the development of a more sensitive and specific lateral flow immunoassay that will utilize highly specific heat shock proteins as antigens. These antigens will be used, in conjunction with quantum dots labels, to achieve hi
gh sensitivity. In Phase I, IOS will demonstrate the superior performance of this assay over the ELISA kits currently used for cutaneous leishmaniasis diagnosis. The use of quantum dots as labels will allow additional antigens to be incorporated, in the fu
ture, to develop a multiplexed lateral flow immunoassay. PUBLIC HEALTH RELEVANCE: Leishmaniasis affects millions of people and causes thousands of deaths annually. Unfortunately, current methods of diagnosis involve labor intensive laboratory based procedu
res, and are not sufficiently sensitive or specific. This application describes a novel method to develop a simple, field-usable, sensitive, and highly specific test kit for leishmaniasis diagnosis.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Research funding history
264 SBIR/STTR records share this UEI (1998–2025). Reported award amounts total $77,140,779. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Defense, Department of Health and Human Services, National Aeronautics and Space Administration, Department of Energy, Environmental Protection Agency, Department of Agriculture
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards